F. Handle

发表

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

H. Klocker, G. Kristiansen, D. Dietrich, 2015, Oncogene.

Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits

A. Tailleux, J. Patsch, P. Eller, 2012, Atherosclerosis.

AR variants: lost in translation to clinical practice?

F. Claessens, F. Handle, 2019, Nature Reviews Urology.

A disease‐associated missense mutation in CYP4F3 affects the metabolism of leukotriene B4 via disruption of electron transfer

Xiao Yin Lee, A. Van Schepdael, F. Claessens, 2022, Journal of cachexia, sarcopenia and muscle.

p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

T. Furlan, G. Schäfer, I. Eder, 2020, Endocrine-related cancer.

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide

H. Klocker, W. Parson, Z. Culig, 2016, Oncotarget.

Molecular underpinnings of enzalutamide resistance.

W. Zwart, A. Houtsmuller, F. Claessens, 2018, Endocrine-related cancer.

Small-molecule profiling for steroid receptor activity using a universal steroid receptor reporter assay

W. Dehaen, F. Claessens, A. Voet, 2021, The Journal of Steroid Biochemistry and Molecular Biology.

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse

M. Nykter, T. Visakorpi, T. Tolonen, 2021, Nature Communications.

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer

M. Nykter, T. Visakorpi, T. Tolonen, 2021, bioRxiv.

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer

F. Claessens, S. Joniau, F. Handle, 2021, Cancers.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

H. Klocker, G. Schaefer, C. Ploner, 2017, Clinical Cancer Research.

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9

G. Schäfer, T. Casneuf, Z. Culig, 2013, Endocrine-related cancer.

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer

M. Gleave, S. Fuessel, E. Juengel, 2020, PloS one.

The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.

J. Rainer, M. Hager, J. Bouchal, 2016, Endocrine-related cancer.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling

N. Maitland, Z. Culig, G. Nappo, 2017, Oncogenesis.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, Oncotarget.

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

G. Cappellano, G. Jenster, H. V. D. van de Werken, 2018, European urology.

IL 6 sensitizes prostate cancer to the antiproliferative effect of IFN a 2 through IRF 9

G. Schäfer, T. Casneuf, Z. Culig, 2013 .

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells

G. Kristiansen, D. Dietrich, W. Parson, 2016, Molecular Cancer Research.

Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer

H. Klocker, H. Hackl, G. Schaefer, 2021, Oncogene.

SOCS 3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells

G. Kristiansen, D. Dietrich, W. Parson, 2016 .

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells

I. Mills, F. Claessens, A. Urbanucci, 2019, Scientific Reports.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

F. Claessens, G. Schaefer, W. V. van Weerden, 2018, Molecular Cancer Therapeutics.

Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy

C. Seifarth, F. Handle, M. Kralinger, 2018, Current eye research.

The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation

K. Verstrepen, M. Poutanen, C. Ohlsson, 2021, EMBO reports.

The oncogenic protein kinase/ATPase RIOK1 is up-regulated via the MYC/E2F transcription factor axis in prostate cancer.

H. Klocker, P. De Wulf, J. Haybaeck, 2023, The American journal of pathology.

Abstract 3: Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015 .

Molecular underpinnings of enzalutamide resistance

W. Zwart, A. Houtsmuller, F. Claessens, 2018, Endocrine-related cancer.

The Prostate

Z. Culig, F. Handle, M. Gruber, 2020 .

MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors.

Z. Trajanoski, W. Parson, T. Furlan, 2021, The American journal of pathology.

Antizyme Inhibitor 1 regulates matrikine expression and enhances the metastatic potential of aggressive primary prostate cancer.

D. Lambrechts, E. Davicioni, T. Gevaert, 2022, Molecular cancer research : MCR.

CDK12/13 inhibition in ovarian cancer cell lines

M. Ausserlechner, C. Marth, F. Handle, 2023, Geburtshilfe und Frauenheilkunde.

Molecular underpinnings of enzalutamide resistance.

W. Zwart, A. Houtsmuller, F. Claessens, 2018, Endocrine-related cancer.

Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.

H. Hackl, C. Ploner, A. Pircher, 2023, Oncogene.

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

H. Klocker, C. Ploner, N. Maitland, 2015, OncoTarget.